

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to: Commissioner for Patents, Washington, D.C. 20231 on February 2, 2002.

Printed: Katherine Stofer

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of: Lal et al.

RECEIVED

MAR 15 2002

Title: HUMAN REGULATORY MOLECULES

Serial No.: 09/840,787

Filing Date: September 20, 2001

TECH CENTER 1600/2900

Examiner: Slobodyansky, E.

Group Art Unit: 1652

Commissioner for Patents
Washington, D.C. 20231

RECEIVED

MAR 4 2002

TECH CENTER 1600/2900

AMENDMENT TRANSMITTAL FEE SHEET

Sir:

Transmitted herewith are the following for the above-identified application:

1. Return Postcard;
2. Transmittal Fee Sheet(1 page, in duplicate);and
3. Response to Restriction Requirement (4 pages).

The fee has been calculated as shown below.

Claims	Claims After Amendment		Claims Previously Paid For	=	Present Extra	Other Than Small Entity Rate Fee	Additional Fee(s)
Total Claims	13	-	20	=		\$18	\$ 0
Indep. Claims	2	-	3	=		\$84	\$0
___ First Presentation of Multiple Dependent Claim						+\$280	\$ 0
TOTAL							\$ 0

- ☒ No additional fee is required.
- ___ Fee for Request for Extension of Time (___ months) \$ ___
- ___ Please charge Deposit Account No. 09-0108 the amount of \$ ___

The Commissioner is hereby authorized to charge any additional fees required under 37 CFR 1.16 and 1.17, or credit overpayment to Deposit Account No. 09-0108. A duplicate copy of this sheet is enclosed.

Respectfully submitted,

INCYTE GENOMICS, INC.

Date: 4 February 2002



Lynn E. Murry, Ph.D.

Reg. No. 42,918

Direct Dial Telephone: (650) 845-4159

3160 Porter Drive
Palo Alto, California 94304
Phone: (650) 855-0555
Fax: (650) 849-8886



COPY OF PAPER
ORIGINALLY FILED

PF-0356-3DIV

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to: Commissioner for Patents, Washington, DC 20231 on 4 February 2002

Printed: Katherine Stofer Signed:

RECEIVED

MAR 15 2002

RECEIVED

MAR - 4 2002

TECH CENTER 1600/2900

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of: Lal, et al.

Title: HUMAN REGULATORY MOLECULES

Serial No.: 09/840,787

Filing Date: 26 September 2001

Examiner: E. Slobodyansky

Group Art Unit: 1652

Commissioner for Patents
Washington, DC 20231

7/a
M.G.J.
3/19/02

RESPONSE TO RESTRICTION REQUIREMENT UNDER 35 USC 121

Sir:

This is a response to the Restriction Requirement mailed 2 January 2002. In that 2 February 2002 fell on a Saturday, this response is timely filed.

The Examiner has listed the following Groups:

Groups 1-49	Claims 1, 15-17 (in part)	polypeptide and method of using
Groups 50-98	Claims 2-14 (in part)	polynucleotide and method of using
Groups 99-147	Claims 18-20 (in part)	antibody and method of using

Applicants hereby elect, with traverse, Group 68, the polynucleotide represented by SEQ ID NO:68 that encodes the protein of SEQ ID NO:19.

AMENDMENT

Please cancel claims 1 and 15-20 without prejudice.

85
4/23/02
Please amend claims ²⁻⁴1-3 as shown in the attached "VERSION WITH MARKINGS TO SHOW CHANGES MADE".

For the Examiner's convenience, the pending claims are shown below.

- a!
- (Once Amended) An isolated polynucleotide comprising a nucleic acid sequence encoding a protein having the amino acid sequence of SEQ ID NO:19 or the complete complement of the polynucleotide.
 - (Once Amended) A composition comprising the polynucleotide of claim 2 and a reporter molecule.
 - (Once Amended) An isolated polynucleotide consisting of the nucleic acid sequence of SEQ ID NO:68 or the complete complement of the polynucleotide.